Emerging role of circulating tumor DNA for early detection of recurrence in biliary tract cancers.

Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-224/coif). B.B. is supported by the Defense Congressionally Directed Medical Research Program # W81XWH-22-1-0208. B.B. served on advisory board for Merck/Eisai, Fate Therapeutics and KAHR Medical. B.B. reports research funding to institution from Amgen, Inc., Boehringer Ingelheim, Bicycle Therapeutics, Elucida Oncology, Gritstone Bio, Ikena Oncology, Jazz Pharmaceuticals, KAHR Medical, Lyell immunopharma, Merck, PionyrImmunopharma, Rascal Therapeutics, Syros Pharmaceuticals, Tarveda Therapeutics, all outside the submitted work. The other author has no conflicts of interest to declare.